Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication

Acta Ophthalmologica

Volumn 92, Issue 2, 2014, Pages 149-157

  Kjellström, Ulrika ^a   Andréasson, Sten ^a   Ponjavic, Vesna ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

anti epileptic drug; drug toxicity; full field electroretinography; optical coherence tomography; vigabatrin; visual field defect

Indexed keywords

VIGABATRIN;

A WAVE; ADULT; AGED; ARTICLE; B WAVE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; COMPUTER ASSISTED PERIMETRY; CONTROLLED STUDY; ELECTRORETINOGRAPHY; EYE FUNDUS; FEMALE; HUMAN; MALE; MIDDLE AGED; NERVE CELL; OPTICAL COHERENCE TOMOGRAPHY; OSCILLATORY POTENTIAL; OUTCOME ASSESSMENT; PHOTORECEPTOR; PRIORITY JOURNAL; RETINA; RETINAL NERVE FIBER LAYER THICKNESS; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL SYSTEM FUNCTION;

ANTI-EPILEPTIC DRUG; DRUG TOXICITY; FULL-FIELD ELECTRORETINOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; VIGABATRIN; VISUAL FIELD DEFECT;

ADULT; AGED; ANTICONVULSANTS; ELECTRORETINOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE FIBERS; OPTIC DISK; REFRACTION, OCULAR; RETINA; RETINAL GANGLION CELLS; TOMOGRAPHY, OPTICAL COHERENCE; VIGABATRIN; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84896724777     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12030     Document Type: Article

References (56)

1. Akcakaya AA, Gokceer S, Erbil HH, et al., (2010): Detecting retinal vigabatrin toxicity in patients with partial symptomatic or cryptogenic epilepsy. Eur J Ophthalmol 20: 763-769.
2. Ben-Menachem E, (1995): Vigabatrin. Epilepsia 36 (Suppl 2): S95-S104.
3. Besch D, Kurtenbach A, Apfelstedt-Sylla E, Sadowski B, Dennig D, Asenbauer C, Zrenner E, &, Schiefer U, (2002): Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 104: 151-170.
4. Brown KT, (1968): The electroretinogram: its components and their origins. Vision Res 8: 633-677.
5. Budenz DL, Michael A, Chang RT, McSoley J, &, Katz J, (2005): Sensitivity and specificity of the StratusOCT for perimetric glaucoma. Ophthalmology 112: 3-9.
6. Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, &, Logan WJ, (2004): Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111: 1935-1942.
7. Clayton LM, Devile M, Punte T, Kallis C, de Haan GJ, Sander JW, Acheson J, &, Sisodiya SM, (2011): Retinal nerve fiber layer thickness in vigabatrin-exposed patients. Ann Neurol 69: 845-854.
8. Comaish IF, Gorman C, Brimlow GM, Barber C, Orr GM, &, Galloway NR, (2002): The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol 104: 195-212.
9. Cosi V, Callieco R, Galimberti CA, Manni R, Tartara A, Mumford J, &, Perucca E, (1989): Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 27 (Suppl 1): 61S-68S.
10. Cubells JF, Blanchard JS, Smith DM, &, Makman MH, (1986): In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina vs. brain. J Pharmacol Exp Ther 238: 508-514.
11. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, &, Zackon D, (1999): Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 106: 1792-1798.
12. Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, &, Picaud S, (2004): Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol 55: 695-705.
13. Durnian JM, &, Clearkin LG, (2008): Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss - could scanning laser polarimetry aid diagnosis? Eye 22: 559-563.
14. Elterman RD, Shields WD, Mansfield KA, &, Nakagawa J, (2001): Randomized trial of vigabatrin in patients with infantile spasms. Neurology 57: 1416-1421.
15. Frisen L, &, Malmgren K, (2003): Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81: 466-473.
16. Garway-Heath DF, Poinoosawmy D, Fitzke FW, &, Hitchings RA, (2000): Mapping the visual field to the optic disc in normal tension glaucoma eyes. Ophthalmology 107: 1809-1815.
17. Graniewski-Wijnands HS, &, van der Torren K, (2002): Electro-ophthalmological recovery after withdrawal from vigabatrin. Doc Ophthalmol 104: 189-194.
18. Hammond EJ, Rangel RJ, &, Wilder BJ, (1988): Evoked potential monitoring of vigabatrin patients. Br J Clin Pract Suppl 61: 16-23.
19. Harding GF, Wild JM, Robertson KA, Lawden MC, Betts TA, Barber C, &, Barnes PM, (2000a): Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 41: 1420-1431.
20. Harding GF, Wild JM, Robertson KA, Rietbrock S, &, Martinez C, (2000b): Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 55: 347-352.
21. Hardus P, Verduin W, Berendschot T, Postma G, Stilma J, &, van Veelen C, (2003): Vigabatrin: longterm follow-up of electrophysiology and visual field examinations. Acta Ophthalmol Scand 81: 459-465.
22. Izumi Y, Ishikawa M, Benz AM, Izumi M, Zorumski CF, &, Thio LL, (2004): Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia 45: 1043-1048.
23. Jammoul F, Wang Q, Nabbout R, et al., (2009): Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 65: 98-107.
24. Johnson MA, Krauss GL, Miller NR, Medura M, &, Paul SR, (2000): Visual function loss from vigabatrin: effect of stopping the drug. Neurology 55: 40-45.
25. Kalviainen R, Nousiainen I, Mantyjarvi M, Nikoskelainen E, Partanen J, Partanen K, &, Riekkinen P Sr, (1999): Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 53: 922-926.
26. Kjellstrom U, Lovestam-Adrian M, Andreasson S, &, Ponjavic V, (2008): Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy. Doc Ophthalmol 117: 93-101.
27. Kjellstrom U, Bruun A, Ghosh F, Andreasson S, &, Ponjavic V, (2009): Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication. Effect of vigabatrin in the rabbit eye. Graefes Arch Clin Exp Ophthalmol 247: 1057-1067.
28. Krauss GL, Johnson MA, Sheth S, &, Miller NR, (2003): A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 74: 339-343.
29. Lawden MC, Eke T, Degg C, Harding GF, &, Wild JM, (1999): Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67: 716-722.
30. Lawthom C, Smith PE, &, Wild JM, (2009): Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Ophthalmology 116: 565-571.
31. Liegeois-Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, &, Chauvel P, (1989): Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients. Epilepsia 30 (Suppl 3): S23-S25.
32. Lux AL, Edwards SW, Hancock E, et al., (2005): The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 4: 712-717.
33. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, &, Bach M, (2009): ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 118: 69-77.
34. Mauguiere F, Chauvel P, Dewailly J, &, Dousse N, (1997): No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group. Epilepsia 38: 301-308.
35. Medeiros FA, Zangwill LM, Alencar LM, Bowd C, Sample PA, Susanna R, &, Weinreb RN, (2009): Detection of Glaucoma Progression using Stratus OCT Retinal Nerve Fiber Layer, Optic Nerve Head and Macular Thickness Measurements. Invest Ophthalmol Vis Sci 50: 5741-5748.
36. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, &, Krauss GL, (1999): Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 53: 2082-2087.
37. Mitchell WG, &, Shah NS, (2002): Vigabatrin for infantile spasms. Pediatr Neurol 27: 161-164.
38. Moseng L, Saeter M, Morch-Johnsen GH, Hoff JM, Gajda A, Brodtkorb E, &, Midelfart A, (2011): Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. Acta Ophthalmol 89: 452-458.
39. Neal MJ, Cunningham JR, Shah MA, &, Yazulla S, (1989): Immunocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina. Neurosci Lett 98: 29-32.
40. Newman WD, Tocher K, &, Acheson JF, (2002): Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 16: 567-571.
41. Nicolson A, Leach JP, Chadwick DW, &, Smith DF, (2002): The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 73: 327-329.
42. Nomoto H, Matsumoto C, Takada S, Hashimoto S, Arimura E, Okuyama S, &, Shimomura Y, (2009): Detectability of glaucomatous changes using SAP, FDT, flicker perimetry, and OCT. J Glaucoma 18: 165-171.
43. Nousiainen I, Mantyjarvi M, &, Kalviainen R, (2001): No reversion in vigabatrin-associated visual field defects. Neurology 57: 1916-1917.
44. Pierro L, Gagliardi M, Iuliano L, Ambrosi A, &, Bandello F, (2012): Retinal Fiber Layer Thickness Reproducibility Using Seven Different OCT Instruments. Invest Ophthalmol Vis Sci 53: 5912-5920.
45. Ponjavic V, &, Andreasson S, (2001): Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 102: 63-72.
46. Ponjavic V, Granse L, Kjellstrom S, Andreasson S, &, Bruun A, (2004): Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin. Doc Ophthalmol 108: 125-133.
47. Ravindran J, Blumbergs P, Crompton J, Pietris G, &, Waddy H, (2001): Visual field loss associated with vigabatrin: pathological correlations. J Neurol Neurosurg Psychiatry 70: 787-789.
48. Schmidt T, Ruther K, Jokiel B, Pfeiffer S, Tiel-Wilck K, &, Schmitz B, (2002): Is visual field constriction in epilepsy patients treated with vigabatrin reversible? J Neurol 249: 1066-1071.
49. Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, &, Brodie MJ, (2003): Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 44: 886-892.
50. van der Torren K, Graniewski-Wijnands HS, &, Polak BC, (2002): Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol 104: 181-188.
51. Van Ghelue M, Eriksen HL, Ponjavic V, et al., (2000): Autosomal dominant cone-rod dystrophy due to a missense mutation (R838C) in the guanylate cyclase 2D gene (GUCY2D) with preserved rod function in one branch of the family. Ophthalmic Genet 21: 197-209.
52. Vanhatalo S, Nousiainen I, Eriksson K, et al., (2002): Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 43: 748-756.
53. Wachtmeister L, (1998): Oscillatory potentials in the retina: what do they reveal. Prog Retin Eye Res 17: 485-521.
54. Wild JM, Martinez C, Reinshagen G, &, Harding GF, (1999): Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40: 1784-1794.
55. Wild JM, Robson CR, Jones AL, Cunliffe IA, &, Smith PE, (2006): Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 47: 917-924.
56. Yalvac IS, Altunsoy M, Cansever S, Satana B, Eksioglu U, &, Duman S, (2009): The correlation between visual field defects and focal nerve fiber layer thickness measured with optical coherence tomography in the evaluation of glaucoma. J Glaucoma 18: 53-61.